Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12524878 | 0.86 | MRGPRX4 (0.50) | MRGPRX4S1PR4FFAR1BDKRB2CYP3A4 | |
| SCHEMBL1016955 | 0.83 | SYK (0.50) | MRGPRX4SYKS1PR4FFAR1NPC1 | |
| SCHEMBL29963026 | 0.83 | SYK (0.50) | MRGPRX4SYKS1PR4FFAR1NPC1 | |
| SCHEMBL23538130 | 0.82 | SYK (0.45) | MRGPRX4SYKS1PR4FFAR1CYP3A4 | |
| SCHEMBL15701535 | 0.81 | RXRA (0.49) | MRGPRX4S1PR4FFAR1BDKRB2 | |
| SCHEMBL23537899 | 0.80 | MRGPRX4 (0.43) | MRGPRX4SYKS1PR4NPC1LMNA | |
| SCHEMBL2702047 | 0.80 | SYK (0.52) | MRGPRX4SYKS1PR4CYP3A4NPC1 | |
| SCHEMBL29945002 | 0.80 | SYK (0.52) | MRGPRX4SYKS1PR4CYP3A4NPC1 | |
| SCHEMBL29944991 | 0.80 | SYK (0.52) | MRGPRX4SYKS1PR4CYP3A4NPC1 | |
| SCHEMBL4798371 | 0.77 | CYP3A4 (0.40) | S1PR4CYP3A4LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699798-A4 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1699798-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7064203-B2 | Di-substituted pyrrolotriazine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005065266-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | ERBB2, ERBB4, EGFR | MRGPRX4 1455/4885SYK 415/4885S1PR4 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.